Key Finding
Chemotherapy in breast cancer patients causes significant gray matter reductions and functional hypoactivation in brain regions governing cognitive control and emotional regulation, with higher education levels potentially offering neuroprotective effects.
Chemotherapy is a life-saving treatment for breast cancer, but it can sometimes cause cognitive problems that patients describe as "chemo brain." Researchers wanted to understand exactly what happens in the brain during chemotherapy by analyzing 29 different brain imaging studies involving breast cancer patients.
The study found that chemotherapy causes measurable changes in both brain structure and function. Patients who received chemotherapy showed reduced gray matter (the brain tissue responsible for processing information) in several important areas. These included regions involved in decision-making, emotional regulation, and cognitive control, such as the orbitofrontal cortex, anterior cingulate cortex, insula, and cerebellum. The brain scans also showed reduced activity in some of these same regions, particularly the insula and rolandic operculum.
Interestingly, researchers found that education level appeared to offer some protection against these brain changes. Patients with higher education levels showed better preservation of brain structure, possibly because they had greater "cognitive reserve" to draw upon during treatment.
These findings help explain why some breast cancer patients experience memory problems, difficulty concentrating, or emotional changes during and after chemotherapy. Understanding these brain changes is the first step toward developing better supportive treatments.
For patients experiencing chemo brain symptoms, acupuncture may offer supportive care alongside conventional treatment. Research suggests acupuncture may help with cognitive function, fatigue, and overall well-being during cancer treatment. If you're interested in exploring acupuncture as part of your integrative cancer care plan, work with a licensed acupuncturist experienced in oncology support.
This coordinate-based meta-analysis examined neuroimaging data from 29 studies investigating brain changes in breast cancer patients following chemotherapy. Using structural MRI, diffusion tensor imaging, and resting-state functional MRI, researchers compared chemotherapy-treated patients to chemotherapy-naive controls.
Key structural findings revealed significant gray matter reductions in the orbitofrontal cortex, anterior cingulate cortex, insula, cerebellum, and rolandic operculum. Functional imaging demonstrated hypoactivation in the rolandic operculum and insula. These regions are primarily associated with cognitive control, emotional regulation, and interoceptive processing.
Education level emerged as a potential protective factor, correlating with preserved gray matter integrity and suggesting cognitive reserve may buffer chemotherapy-related neurotoxicity.
Clinical implications: These findings provide neurobiological evidence for chemotherapy-related cognitive impairment (CRCI) in breast cancer patients. The consistent patterns of gray matter loss and functional hypoactivation in emotion and cognition-related regions support integrative approaches targeting neuroplasticity and neuroprotection. Acupuncture practitioners should consider these neurotoxic effects when developing treatment protocols for post-chemotherapy cognitive symptoms, with potential focus on executive function and emotional regulation support.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Acupuncture significantly improved total sleep time by approximately 30 minutes and sleep efficiency by 4.56% compared to control groups in breast cancer patients with systemic therapy-associated insomnia.
📌 Cognitive behavioral therapy and hypnosis have the strongest evidence for reducing vasomotor symptoms in breast cancer survivors, while acupuncture may provide modest benefit as an adjunctive nonpharmacological treatment option.
📌 Traditional acupuncture reduced hot flash and night sweat frequency by nearly 50% in breast cancer survivors taking tamoxifen, with sustained effects lasting at least 18 weeks after treatment ended.